Aducanumab

Research use only, not for human use.

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.

——

Animal Model:9.5- to 15.5-month-old Tg2576 transgenic mice Dosage:0.3-30 mg/kg Administration:Intraperitoneal injection (i.p.), weekly, 6 months Result: Increased recruitment of Iba-1-positive microglia to Aβ plaques.Animal Model:18-month-old Tg2576 mice Dosage:10 mg/kg Administration:Intraperitoneal injection (i.p.), weekly, 6 months Result:Restored neurite baseline calcium to control levels.Decreased the number of neurites with elevated levels of calcium after 2 weeks.Decreased the percentage of cell bodies with calcium overload.Restored the levels of VILIP and SERCA to control levels.Increased the cell numbers of NR1 and NR2A.Animal Model:22-month-old transgenic Tg2576 mice Dosage:0.4-1 mg/mL Administration: Intracerebroventricular injection (ICV), 20 minResult:Decreased the number of amyloid plaque.Decreased the size of the remaining individual plaques.Reduced amyloid plaque burden.

——

Membrane Transporter/Ion Channel

Beta Amyloid

Beta Amyloid

——

——

1384260-65-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years